Salvia BioElectronics

High-Level Overview

Salvia BioElectronics is a clinical-stage medical device company developing MySalvia Therapy, a paper-thin, implantable neuromodulation device for chronic migraine relief, activated via a wearable tap for drug-free nerve calming.[1][2] It targets over one billion migraine sufferers worldwide—the leading cause of disability under age 50—and explores cluster headache applications, serving patients seeking uninterrupted lives without daily medications.[1][3] With a $60M oversubscribed Series B in 2025, the Eindhoven-based firm (50+ global team) advances U.S., European, and Australian clinical trials toward market entry.[2][5]

Origin Story

Founded March 3, 2017, in Eindhoven—Europe's tech capital—by Hubert Martens, Daniel Schobben, and Wim Pollet, all MedTech veterans in medical devices and neuromodulation.[1][2] Starting from "innovative ideas and a blank whiteboard," they prioritized patient and clinician needs to design the implant's form and functions.[1] Pivotal growth includes eight years of scaling to 50+ multidisciplinary staff at High Tech Campus Eindhoven, plus the 2025 Series B to propel clinical development.[2]

Core Differentiators

• Ultra-thin, patient-centric implant: Paper-thin, unnoticeable design for daily wear, activated by tapping a small wearable—delivering on-demand, drug-free neuromodulation without lifestyle compromise.[1][2]
• Neuromodulation precision: Targets migraine-triggering nerves; bioelectronic approach redefines therapy, with future MySalvia app for condition management.[1]
• Proven team and ecosystem: MedTech experts from a "smartest square kilometer" hub, backed by leading investors for rapid clinical progress.[1][2]
• Dual-condition potential: Core migraine focus plus cluster headache exploration, addressing high unmet needs in neurology.[1][3]

Role in the Broader Tech Landscape

Salvia rides the bioelectronics and neuromodulation wave, shifting neurology from pharmaceuticals to precise, implantable tech amid rising chronic pain demands.[1][4] Timing aligns with migraine's massive burden (1B+ affected) and limitations of current treatments, fueled by investor confidence via $60M Series B.[2][5] Market tailwinds include High Tech Campus synergies, global clinical reach (U.S./Europe/Australia), and scale-up hiring, positioning Salvia to influence MedTech by enabling drug-free alternatives in a $50B+ headache market.[1][2]

Quick Take & Future Outlook

Clinical trials progress toward approval, with Series B funding accelerating market entry for MySalvia Therapy and app integration.[1][2] Neuromodulation trends, AI-enhanced devices, and personalized medicine will shape growth, potentially expanding to more pain indications. Salvia's patient-first bioelectronics could reclaim lives for millions, transforming migraine from "just a headache" into a manageable condition.[1]